

DAFTAR PUSTAKA

1. Depkes. InfoDATIN Pusat Data dan Informasi Kementerian Kesehatan RI: Situasi Penyakit Ginjal Kronis. 1–10 (2017).
2. Centers for Disease Control and Prevention. National Chronic Kidney Disease Fact Sheet 2017. *US Dep. Heal. Hum. Serv. Cent. Dis. Control Prev.* 1–4 (2017).
3. Murphree, D. D. & Thelen, S. M. Chronic kidney disease in primary care. *J. Am. Board Fam. Med.* **23**, 542–550 (2010).
4. Wang, H. *et al.* Urinary fibrinogen as a predictor of progression of CKD. *Clin. J. Am. Soc. Nephrol.* **12**, 1922–1929 (2017).
5. Valerie A Luyckx, M. T. b & J. W. S. The global burden of kidney disease and the sustainable development goals. <https://www.who.int/bulletin/volumes/96/6/17-206441/en/>.
6. World Kidney Day. Chronic Kidney Disease. <https://www.worldkidneyday.org/facts/chronic-kidney-disease/>.
7. Anothaisintawee, T., Rattanasiri, S., Ingsathit, A., Attia, J. & Thakkinstian, A. Prevalence of chronic kidney disease: A systematic review and meta-analysis. *Clin. Nephrol.* **71**, 244–254 (2009).
8. Kementerian Kesehatan RI Badan Penelitian dan Pengembangan. Hasil Utama Riset Kesehatan Dasar. *Kementerian Kesehat. Republik Indones.* 1–100 (2018) doi:1 Desember 2018.
9. Bae, E. H. *et al.* GFR and cardiovascular outcomes after acute myocardial infarction: Results from the Korea acute myocardial infarction registry. *Am. J. Kidney Dis.* **59**, 795–802 (2012).
10. Hidayati, T. & Kushadiwijaya, H. Hubungan Antara Hipertensi, Merokok Dan Minuman Suplemen Energi Dan Kejadian Penyakit Ginjal Kronik. *Ber. Kedokt. Masy.* **24**, 90–102 (2008).
11. Levey, A. S., Coresh, J. & Van Lente, F. Estimated Glomerular Filtration Rate. *Ann. Intern. Med.* **146**, 74 (2007).
12. Prinsen, B. H. C. M. T. *et al.* Increased albumin and fibrinogen synthesis rate in patients with chronic renal failure. *Kidney Int.* **64**, 1495–1504 (2003).
13. Lutz, J., Menke, J., Sollinger, D., Schinzel, H. & Thürmel, K. Haemostasis in chronic kidney disease. *Nephrol. Dial. Transplant.* **29**, 29–40 (2014).

14. Schei, J. *et al.* Residual associations of inflammatory markers with eGFR after accounting for measured GFR in a community-based cohort without CKD. *Clin. J. Am. Soc. Nephrol.* **11**, 280–286 (2016).
15. Tan, X. *et al.* Indoxyl sulfate, a valuable biomarker in chronic kidney disease and dialysis. *Hemodial. Int.* **21**, 161–167 (2017).
16. Machlus, K. R., Cardenas, J. C., Church, F. C. & Wolberg, A. S. Causal relationship between hyperfibrinogenemia, thrombosis, and resistance to thrombolysis in mice. *Blood* **117**, 4953–4963 (2011).
17. Moore KL, Dalley IIAF, Agur AMR. Clinically Oriented Anatomy Eight Edition. Wolters Kluwer Health; 2018. 1153 p.
18. Tortora GJ, Derrickson B. Principles of Anatomy & Physiology. Wiley; 2017.
19. Victor P. Eroschenko. Atlas Histologi diFiore dengan Korelasi Fungsional. 12th ed. EGC; 2015.
20. Lauralee Sherwood. Fisiologi Manusia Dari Sel ke Sistem. 8th ed. EGC; 2016.
21. Guyton dan Hall. Buku Ajar Fisiologi Kedokteran. 12th ed. Elsevier; 2016.
22. Prinsen BHCMT, Rabelink TJ, Beutler JJ, Kaysen GA, De Boer J, Boer WH, et al. Increased albumin and fibrinogen synthesis rate in patients with chronic renal failure. *Kidney Int.* 2003;64(4):1495–504.
23. Rodwell V. Harper's Illustrated Biochemistry. 31st ed. Mc Graw Hill LANGE; 2018.
24. Weisel BJW. FIBRINOGEN AND FIBRIN. 2005;70(04):247–99.
25. Lowe GDO, Rumley A, Mackie IJ. Review Article Plasma fibrinogen. 2004;
26. Journal O, Society I. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. 2013;3(1).
27. <https://www.medscape.com/answers/238798-105274/what-is-the-global-prevalence-of-chronic-kidney-disease-ckd>.
28. Carney EF. The impact of chronic kidney disease on global health. *Nat Rev Nephrol* [Internet]. 2020;41581. Available from: <http://dx.doi.org/10.1038/s41581-020-0268-7>

29. Gansevoort RT, Correa-rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJL, Mann JF. Global Kidney Disease 5 Chronic kidney disease and cardiovascular risk : epidemiology , mechanisms , and prevention. *Lancet* [Internet]. 2013;382(9889):339–52. Available from: [http://dx.doi.org/10.1016/S0140-6736\(13\)60595-4](http://dx.doi.org/10.1016/S0140-6736(13)60595-4)
30. Kazanciog R. Risk factors for chronic kidney disease : an update. 2013;368–71.
31. McClellan WM, Flanders WD. Risk Factors for Progressive Chronic Kidney Disease. 2003;(8):65–70.
32. Cobo G, Hecking M, Port FK, Exner I, Lindholm B, Stenvinkel P, et al. Sex and gender differences in chronic kidney disease : progression to end-stage renal disease and haemodialysis. 2016;1147–63.
33. Sabljar M. 1 . PATHOPHYSIOLOGY AND CLASSIFICATION OF KIDNEY. 2009;20(December 2004):2–11.
34. Fauci AS. *Harrison's Principle of Internal Medicine*. 17th ed. Mc Graw Hill;
35. Webster AC, Nagler E V, Morton RL, Masson P. Seminar Chronic kidney disease. *Lancet* [Internet]. 2017;389(10075):1238–52. Available from: [http://dx.doi.org/10.1016/S0140-6736\(16\)32064-5](http://dx.doi.org/10.1016/S0140-6736(16)32064-5)
36. Article R. Detailed Review of Chronic Kidney Disease. 2019;
37. Matica J. disease : national recommendations. 2017;27(1):153–76.
38. Meola M. Imaging in Chronic Kidney Disease. 2016;188:69–80.
39. Carvalho ARM, Pinto CMA, Andriolo A, Guerra IC. Laboratory diagnosis of chronic kidney disease in adults : an overview of hospitals inserted in the Portuguese National Health System. 2017;(December):388–96.
40. Kidney C, Guideline D, Clinical A, Oversight G. Management of Chronic Kidney Disease Key points. 2019;(July).
41. Chen T, Harris DC. Challenges of chronic kidney disease prevention. 2015;203(5):5–7.
42. Luyckx VA, Tuttle KR, Garcia-garcia G, Massy ZA, Moe O, Nelson RG, et al. Reducing major risk factors for chronic kidney disease. *Kidney Int*

- Suppl [Internet]. 2017;7(2):71–87. Available from: <http://dx.doi.org/10.1016/j.kisu.2017.07.003>
43. Thomas R, Kanso A, Sedor JR. Chronic Kidney Disease and Its Complications. 2008;35:329–44.
 44. Nangaku M, Powe NR, White SL, Wheeler DC. Complications of chronic kidney disease: current state, knowledge gaps, and strategy for action. 2017;122–9.
 45. Shankar O, Sah P, Qing YX. Associations Between Hyperuricemia and Chronic Kidney Disease : A Review. 2015;7(3).
 46. Vinuesa D, Go F, Verdalles U, Mosse A. Serum fibrinogen levels are an independent predictor of mortality in patients with chronic kidney disease stages 3 and 4. 2008;68.
 47. Nunns GR, Moore EE, Chapman MP, Moore HB, Stettler GR, Peltz E, et al. The American Journal of Surgery The hypercoagulability paradox of chronic kidney disease : The role of fi brinogen. Am J Surg [Internet]. 2017;214(6):1215–8. Available from: <https://doi.org/10.1016/j.amjsurg.2017.08.039>
 48. Huang M, Wei R, Wang Y, Su T, Di P, Li Q, et al. Blood coagulation system in patients with chronic kidney disease : a prospective observational study. 2017;1–8.
 49. Matusik PT, Heleniak Z, Plens K. Chronic Kidney Disease and Its Impact on a Prothrombotic State in Patients with Atrial Fibrillation. 2020;
 50. Brand JA, Van Den, Mutsaers HAM, Zuilen AD Van, Blankestijn J, Broek PH Van Den, Russel FGM, et al. Uremic Solutes in Chronic Kidney Disease and Their Role in Progression. 2016;1–16.
 51. F Panicucci, A Sagripanti, E Pinori, M Vispi, L Lecchini, G Barsotti SG. Comprehensive Study of Haemostasis in Chronic Uremia. 2018;
 52. A. Sagripanti; Cozza; Baicchi; M. Camici; A. Cupisti; G. Barsotti. Increased thrombin generation in patients with chronic renal failure. 2008;72–5.
 53. Wahid I, Acang N, Azmi S. Correlation of Thrombin-Antithrombin

Complex With Indoxyl Sulfate Level in Chronic Kidney Disease Patients. 2019;

54. Davalos D, Akassoglou K. Fibrinogen as a key regulator of inflammation in disease. 2012;43–62.
55. Wang H, Zheng C, Xu X, Zhao Y, Lu Y. Fibrinogen links podocyte injury with Toll-like receptor 4 and is associated with disease activity in FSGS patients. 1992;
56. Wang H, Zheng C, Lu Y, Jiang Q, Yin R, Zhu P, et al. Urinary fibrinogen as a predictor of progression of CKD. *Clin J Am Soc Nephrol.* 2017;12(12):1922–9.

